Bristol Myers Squibb’s mezigdomide continues to build toward regulatory and label strategy after it reported SUCCESSOR-2 success, reinforcing the company’s push for next-generation multiple myeloma therapies. The Phase III portion of the seamless Phase II/III study evaluated mezigdomide added to carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. The readout reported a 52% reduction in the risk of progression or death with the mezigdomide regimen and median PFS reaching 18 months compared with 8.3 months in the control arm. The update followed the company’s earlier March preview of meeting the Phase 3 progression-free survival endpoint. The combined set of disclosures signals that BMS is moving from endpoint hit to the next steps of interaction with regulators on how the benefit-risk profile will be reflected in the label package, including safety and response depth signals.